
|Videos|April 27, 2017
How Oral Targeted Therapies and IV Immunotherapies Disrupted Community Practice Financing
Author(s)Barbara McAneny, MD
Barbara McAneny, MD, the chief executive officer of New Mexico Cancer Center, discusses how oral targeted therapies and immunotherapies disrupted the traditional methods for financing community practices.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
4
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
5








































